Galmed Operating Income vs Other Operating Expenses Analysis

GLMD Stock  USD 2.82  0.06  2.08%   
Galmed Pharmaceuticals financial indicator trend analysis is much more than just examining Galmed Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Galmed Pharmaceuticals is a good investment. Please check the relationship between Galmed Pharmaceuticals Operating Income and its Other Operating Expenses accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.

Operating Income vs Other Operating Expenses

Operating Income vs Other Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Galmed Pharmaceuticals Operating Income account and Other Operating Expenses. At this time, the significance of the direction appears to have pay attention.
The correlation between Galmed Pharmaceuticals' Operating Income and Other Operating Expenses is -0.91. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Other Operating Expenses in the same time period over historical financial statements of Galmed Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Galmed Pharmaceuticals' Operating Income and Other Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Galmed Pharmaceuticals are associated (or correlated) with its Other Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Operating Expenses has no effect on the direction of Operating Income i.e., Galmed Pharmaceuticals' Operating Income and Other Operating Expenses go up and down completely randomly.

Correlation Coefficient

-0.91
Relationship DirectionNegative 
Relationship StrengthSignificant

Operating Income

Operating Income is the amount of profit realized from Galmed Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Galmed Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Galmed Pharmaceuticals. It is also known as Galmed Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.
Most indicators from Galmed Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Galmed Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.At present, Galmed Pharmaceuticals' Sales General And Administrative To Revenue is projected to drop slightly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 0.25, whereas Issuance Of Capital Stock is forecasted to decline to about 5.9 M.
 2021 2022 2023 2024 (projected)
Interest Income562K297K375K747.7K
Net Interest Income519K275K745K775.1K

Galmed Pharmaceuticals fundamental ratios Correlations

-0.210.68-0.37-0.29-0.21-0.22-0.320.280.37-0.24-0.23-0.420.31-0.19-0.11-0.450.66-0.05-0.36-0.07-0.44-0.19-0.39-0.42-0.47
-0.21-0.430.660.581.00.470.42-0.77-0.290.580.76-0.080.151.00.490.66-0.50.530.620.460.151.00.540.080.37
0.68-0.43-0.64-0.6-0.43-0.51-0.480.370.72-0.55-0.3-0.540.3-0.4-0.38-0.820.98-0.14-0.75-0.3-0.71-0.41-0.67-0.56-0.61
-0.370.66-0.640.780.630.750.26-0.41-0.660.720.380.26-0.190.640.620.82-0.710.270.790.620.280.640.420.460.29
-0.290.58-0.60.780.530.630.52-0.18-0.60.990.140.16-0.060.560.850.72-0.570.420.70.940.380.570.530.270.51
-0.211.0-0.430.630.530.440.4-0.79-0.270.530.78-0.070.141.00.440.65-0.50.520.610.40.151.00.530.080.35
-0.220.47-0.510.750.630.440.11-0.24-0.660.550.210.25-0.030.450.40.78-0.480.190.780.530.390.460.320.370.1
-0.320.42-0.480.260.520.40.11-0.44-0.090.520.41-0.070.310.420.560.37-0.450.390.270.410.520.420.72-0.150.9
0.28-0.770.37-0.41-0.18-0.79-0.24-0.440.01-0.15-1.00.11-0.16-0.77-0.06-0.40.46-0.4-0.3-0.01-0.13-0.77-0.520.03-0.42
0.37-0.290.72-0.66-0.6-0.27-0.66-0.090.01-0.580.04-0.760.54-0.24-0.45-0.860.69-0.06-0.91-0.43-0.71-0.25-0.15-0.8-0.27
-0.240.58-0.550.720.990.530.550.52-0.15-0.580.110.14-0.030.560.880.68-0.510.460.680.940.360.570.50.240.49
-0.230.76-0.30.380.140.780.210.41-1.00.040.11-0.150.190.770.040.35-0.390.410.26-0.010.080.760.48-0.080.38
-0.42-0.08-0.540.260.16-0.070.25-0.070.11-0.760.14-0.15-0.87-0.12-0.030.5-0.49-0.040.520.020.69-0.12-0.240.950.3
0.310.150.3-0.19-0.060.14-0.030.31-0.160.54-0.030.19-0.870.180.13-0.210.280.11-0.250.0-0.270.180.46-0.9-0.1
-0.191.0-0.40.640.561.00.450.42-0.77-0.240.560.77-0.120.180.480.63-0.480.530.590.450.121.00.540.030.35
-0.110.49-0.380.620.850.440.40.56-0.06-0.450.880.04-0.030.130.480.55-0.350.430.570.840.260.480.440.090.41
-0.450.66-0.820.820.720.650.780.37-0.4-0.860.680.350.5-0.210.630.55-0.830.270.980.490.690.640.50.580.44
0.66-0.50.98-0.71-0.57-0.5-0.48-0.450.460.69-0.51-0.39-0.490.28-0.48-0.35-0.83-0.13-0.75-0.25-0.65-0.48-0.67-0.53-0.57
-0.050.53-0.140.270.420.520.190.39-0.4-0.060.460.41-0.040.110.530.430.27-0.130.250.430.170.530.24-0.020.37
-0.360.62-0.750.790.70.610.780.27-0.3-0.910.680.260.52-0.250.590.570.98-0.750.250.510.660.60.390.610.34
-0.070.46-0.30.620.940.40.530.41-0.01-0.430.94-0.010.020.00.450.840.49-0.250.430.510.170.460.310.130.36
-0.440.15-0.710.280.380.150.390.52-0.13-0.710.360.080.69-0.270.120.260.69-0.650.170.660.170.120.330.530.67
-0.191.0-0.410.640.571.00.460.42-0.77-0.250.570.76-0.120.181.00.480.64-0.480.530.60.460.120.550.040.35
-0.390.54-0.670.420.530.530.320.72-0.52-0.150.50.48-0.240.460.540.440.5-0.670.240.390.310.330.55-0.240.53
-0.420.08-0.560.460.270.080.37-0.150.03-0.80.24-0.080.95-0.90.030.090.58-0.53-0.020.610.130.530.04-0.240.2
-0.470.37-0.610.290.510.350.10.9-0.42-0.270.490.380.3-0.10.350.410.44-0.570.370.340.360.670.350.530.2
Click cells to compare fundamentals

Galmed Pharmaceuticals Account Relationship Matchups

Galmed Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Common Stock Shares Outstanding1.4M1.4M1.6M1.7M230.8K219.3K
Total Assets77.1M52.4M36.6M16.6M16.6M15.8M
Other Current Liab892K935K966K1.0M830K673.0K
Total Current Liabilities6.9M8.0M5.9M3.1M2.8M4.0M
Total Stockholder Equity69.9M44.2M30.5M13.4M13.9M13.2M
Property Plant And Equipment Net709K570K551K337K125K118.8K
Net Debt(15.6M)(6.7M)(2.7M)(2.0M)(2.8M)(3.0M)
Retained Earnings(106.9M)(135.7M)(168.2M)(186.0M)(193.0M)(183.3M)
Accounts Payable6.0M7.0M4.9M2.6M1.9M3.2M
Cash15.9M6.9M2.9M2.0M2.9M2.7M
Non Current Assets Total709K570K551K1.8M3.4M3.6M
Cash And Short Term Investments75.5M50.9M34.8M13.8M12.6M12.0M
Net Receivables827K812K1.1M124K165K156.8K
Liabilities And Stockholders Equity77.1M52.4M36.6M16.6M16.6M15.8M
Other Current Assets28.1M925K1.2M668K432K410.4K
Other Stockholder Equity176.7M179.5M198.8M200.1M207.1M135.2M
Total Liab7.3M8.2M6.1M3.1M2.8M4.4M
Property Plant And Equipment Gross709K570K551K1.3M1.1M678.5K
Total Current Assets76.4M51.8M36.1M14.7M13.2M12.6M
Accumulated Other Comprehensive Income35K272K(171K)(745K)(454K)(431.3K)
Property Plant Equipment194K709K570K337K387.6K519.1K
Net Tangible Assets15.8M87.9M69.9M44.2M50.8M38.5M
Short Term Investments59.6M43.9M31.9M11.8M9.8M9.3M
Net Invested Capital69.9M44.2M30.5M13.4M13.9M13.2M
Net Working Capital69.5M43.8M30.2M11.6M10.5M10.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Galmed Pharmaceuticals is a strong investment it is important to analyze Galmed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Galmed Pharmaceuticals' future performance. For an informed investment choice regarding Galmed Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
69.72
Return On Assets
(0.29)
Return On Equity
(0.53)
The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.